Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Influenza

  Free Subscription


26.02.2024

4 Ann Intern Med
1 Antimicrob Agents Chemother
3 BMJ
1 Drug Saf
1 Epidemiol Infect
2 J Immunol
14 J Infect Dis
3 J Virol
1 Lancet
3 MMWR Morb Mortal Wkly Rep
3 N Engl J Med
1 PLoS Comput Biol
1 PLoS Med
16 PLoS One
1 Proc Natl Acad Sci U S A
18 Vaccine
2 Virology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Intern Med

  1. CENTOR RM, Tenforde MW, Dawood FS
    Web Exclusive. Annals On Call - Encouraging Influenza Vaccination.
    Ann Intern Med. 2024;177:eA230004.
    PubMed        

  2. WU Q, Tong J, Zhang B, Zhang D, et al
    Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents.
    Ann Intern Med. 2024 Jan 9. doi: 10.7326/M23-1754.
    PubMed         Abstract available

  3. TROY AL, Ahmad I, Zheng Z, Wadhera RK, et al
    Food Insecurity Among Low-Income U.S. Adults During the COVID-19 Pandemic.
    Ann Intern Med. 2024 Jan 2. doi: 10.7326/M23-2282.
    PubMed        

  4. WOLFSON JA, Leung CW
    Food Insecurity in the COVID-19 Era: A National Wake-up Call to Strengthen SNAP Policy.
    Ann Intern Med. 2024 Jan 2. doi: 10.7326/M23-3363.
    PubMed        


    Antimicrob Agents Chemother

  5. PLOTNIK D, Sager JE, Aryal M, Fanget MC, et al
    A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness.
    Antimicrob Agents Chemother. 2024 Feb 20:e0127323. doi: 10.1128/aac.01273.
    PubMed         Abstract available


    BMJ

  6. WORSHAM CM, Bray CF, Jena AB
    Optimal timing of influenza vaccination in young children: population based cohort study.
    BMJ. 2024;384:e077076.
    PubMed         Abstract available

  7. WISE J
    GMC admits error in decision over whether to investigate doctor's claims over covid vaccine.
    BMJ. 2024;384:q433.
    PubMed        

  8. LEMASTERS K, Brinkley-Rubinstein L
    Covid-19 in US jails and prisons: implications for the next public health crisis.
    BMJ. 2024;384:e076975.
    PubMed        


    Drug Saf

  9. WYSZYNSKI DF, Papageorghiou AT, Renz C, Metz TD, et al
    The COVID-19 International Drug Pregnancy Registry (COVID-PR): Protocol Considerations.
    Drug Saf. 2024;47:195-204.
    PubMed         Abstract available


    Epidemiol Infect

  10. GARAY E, Whelan SPJ, DuBois RM, O'Rourke SM, et al
    Immune response to SARS-CoV-2 variants after immunization with different vaccines in Mexico.
    Epidemiol Infect. 2024;152:e30.
    PubMed         Abstract available


    J Immunol

  11. AL-AHMAD A
    Comment on "Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer-BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines".
    J Immunol. 2024;212:753.
    PubMed        

  12. MAINO A, Amen A, Plumas J, Bouquet L, et al
    Development of a New Off-the-Shelf Plasmacytoid Dendritic Cell-Based Approach for the Expansion and Characterization of SARS-CoV-2-Specific T Cells.
    J Immunol. 2024;212:825-833.
    PubMed         Abstract available


    J Infect Dis

  13. MAKHSOUS N, Goya S, Avendano CC, Rupp J, et al
    Within-Host Rhinovirus Evolution in Upper and Lower Respiratory Tract Highlights Capsid Variability and Mutation-Independent Compartmentalization.
    J Infect Dis. 2024;229:403-412.
    PubMed         Abstract available

  14. KARRON RA, Luongo C, Woods S, Oliva J, et al
    Evaluation of the live-attenuated intranasal respiratory syncytial virus (RSV) vaccine RSV/6120/DeltaNS2/1030s in RSV-seronegative young children.
    J Infect Dis. 2023 Jul 26:jiad281. doi: 10.1093.
    PubMed         Abstract available

  15. HEIMONEN J, Chow EJ, Wang Y, Hughes JP, et al
    Risk of Subsequent Respiratory Virus Detection After Primary Virus Detection in a Community Household Study-King County, Washington, 2019-2021.
    J Infect Dis. 2024;229:422-431.
    PubMed         Abstract available

  16. LEROUX-ROELS I, Van Ranst M, Vandermeulen C, Abeele CV, et al
    Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
    J Infect Dis. 2023 Sep 12:jiad321. doi: 10.1093.
    PubMed         Abstract available

  17. MADSEN AMR, Schaltz-Buchholzer F, Nielsen S, Benfield T, et al
    Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: a randomized controlled trial.
    J Infect Dis. 2023 Sep 29:jiad422. doi: 10.1093.
    PubMed         Abstract available

  18. MONROE JM, Quach HQ, Punia S, Enninga EAL, et al
    Vertical Transmission of SARS-CoV-2-Specific Antibodies and Cytokine Profiles in Pregnancy.
    J Infect Dis. 2024;229:473-484.
    PubMed         Abstract available

  19. CASADEVALL A, Sullivan DJ
    Late Administration and Corticosteroid Usage Explain Inefficacy in COVID-19 Convalescent Plasma Trial.
    J Infect Dis. 2024;229:617-618.
    PubMed        

  20. KANBERG N, Grahn A, Stentoft E, Bremell D, et al
    COVID-19 Recovery: Consistent Absence of Cerebrospinal Fluid Biomarker Abnormalities in Patients With Neurocognitive Post-COVID Complications.
    J Infect Dis. 2024;229:493-501.
    PubMed         Abstract available

  21. TURCINOVIC J, Kuhfeldt K, Sullivan M, Landaverde L, et al
    Transmission Dynamics and Rare Clustered Transmission Within an Urban University Population Before Widespread Vaccination.
    J Infect Dis. 2023 Oct 19:jiad397. doi: 10.1093.
    PubMed         Abstract available

  22. YOUNG BR, Ho F, Lin Y, Lau EHY, et al
    Estimation of the Time-Varying Effective Reproductive Number of COVID-19 Based on Multivariate Time Series of Severe Health Outcomes.
    J Infect Dis. 2024;229:502-506.
    PubMed         Abstract available

  23. VUJKOVIC A, Ha M, de Block T, van Petersen L, et al
    Diagnosing Viral Infections Through T-Cell Receptor Sequencing of Activated CD8+ T Cells.
    J Infect Dis. 2024;229:507-516.
    PubMed         Abstract available

  24. GREWAL R, Buchan SA, Nguyen L, Nasreen S, et al
    Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged >/=50 years in Ontario, Canada: a Canadian Immunization Research Network (CIRN) Study.
    J Infect Dis. 2023 Oct 5:jiad419. doi: 10.1093.
    PubMed         Abstract available

  25. ADHIKARI EH, Lu P, Kang YJ, McDonald AR, et al
    Diverging maternal and cord antibody functions from SARS-CoV-2 infection and vaccination in pregnancy.
    J Infect Dis. 2023 Oct 10:jiad421. doi: 10.1093.
    PubMed         Abstract available

  26. HSU FC, Pan LC, Huang YF, Yang CH, et al
    A Dynamic Model for Estimating the Retention Duration of Neutralizing Antibody Titers after Vaccination in a COVID-19 Convalescent Population.
    J Infect Dis. 2023 Oct 5:jiad431. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  27. HSIEH M-S, Hsu C-W, Liao H-C, Lin C-L, et al
    SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters.
    J Virol. 2024 Feb 1:e0154623. doi: 10.1128/jvi.01546.
    PubMed         Abstract available

  28. SHEN S, Guo H, Li Y, Zhang L, et al
    SARS-CoV-2 and oncolytic EV-D68-encoded proteases differentially regulate pyroptosis.
    J Virol. 2024 Jan 30:e0190923. doi: 10.1128/jvi.01909.
    PubMed         Abstract available

  29. UPRETY T, Yu J, Nogales A, Naveed A, et al
    Influenza D virus utilizes both 9-O-acetylated N-acetylneuraminic and 9-O-acetylated N-glycolylneuraminic acids as functional entry receptors.
    J Virol. 2024 Feb 20:e0004224. doi: 10.1128/jvi.00042.
    PubMed         Abstract available


    Lancet

  30. VORA NM, Hassan L, Plowright RK, Horton R, et al
    The Lancet-PPATS Commission on Prevention of Viral Spillover: reducing the risk of pandemics through primary prevention.
    Lancet. 2024;403:597-599.
    PubMed        


    MMWR Morb Mortal Wkly Rep

  31. MUSA N, Ghoniem A, Hsu CH, Mubarak S, et al
    Progress Toward Measles Elimination - World Health Organization Eastern Mediterranean Region, 2019-2022.
    MMWR Morb Mortal Wkly Rep. 2024;73:139-144.
    PubMed         Abstract available

  32. FORD ND, Agedew A, Dalton AF, Singleton J, et al
    Notes from the Field: Long COVID Prevalence Among Adults - United States, 2022.
    MMWR Morb Mortal Wkly Rep. 2024;73:135-136.
    PubMed        

  33. EDENS C, Clopper BR, DeVies J, Benitez A, et al
    Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018-2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:149-151.
    PubMed        


    N Engl J Med

  34. BENEZECH S, Khoryati L, Belot A
    More on Pre-Covid-19, SARS-CoV-2-Negative MIS-C. Reply.
    N Engl J Med. 2024;390:771-772.
    PubMed        

  35. FRANCO A, Tremoulet A, Burns JC
    More on Pre-Covid-19, SARS-CoV-2-Negative MIS-C.
    N Engl J Med. 2024;390:771.
    PubMed        

  36. HERBERT C, McManus DD, Soni A
    Persistent False Positive Covid-19 Rapid Antigen Tests.
    N Engl J Med. 2024;390:764-765.
    PubMed        


    PLoS Comput Biol

  37. LAMB KD, Luka MM, Saathoff M, Orton RJ, et al
    Mutational signature dynamics indicate SARS-CoV-2's evolutionary capacity is driven by host antiviral molecules.
    PLoS Comput Biol. 2024;20:e1011795.
    PubMed         Abstract available


    PLoS Med

  38. NICKEL NC, Phillips-Beck W, Enns JE, Ekuma O, et al
    COVID-19 diagnostic testing and vaccinations among First Nations in Manitoba: A nations-based retrospective cohort study using linked administrative data, 2020-2021.
    PLoS Med. 2024;21:e1004348.
    PubMed         Abstract available


    PLoS One

  39. PELLETIER C, Gagnon D, Dube E
    "It's not that I don't trust vaccines, I just don't think I need them": Perspectives on COVID-19 vaccination.
    PLoS One. 2024;19:e0293643.
    PubMed         Abstract available

  40. RUCHIWIT P, Madua J, Saiphoklang N
    Comparison of ROX, HROX, and delta-HR indices to predict successful weaning from high-flow oxygen therapy in hospitalized patients with COVID-19 pneumonia.
    PLoS One. 2024;19:e0297624.
    PubMed         Abstract available

  41. TAKEBAYASHI M, Namba M, Kaneda Y, Koyama T, et al
    How can we promote vaccination of the mass population?-Lessons from the COVID-19 vaccination defaults.
    PLoS One. 2024;19:e0298983.
    PubMed         Abstract available

  42. ELBEJJANI M, Mansour S, Hammoud RA, Ziade C, et al
    Mental health during the COVID-19 pandemic and first lockdown in Lebanon: Risk factors and daily life difficulties in a multiple-crises setting.
    PLoS One. 2024;19:e0297670.
    PubMed         Abstract available

  43. WEISE V, Guttner F, Staudt A, Mack JT, et al
    Relationship satisfaction and family routines of young parents before and during the first year of the COVID-19 pandemic: A latent growth curve analysis.
    PLoS One. 2024;19:e0297740.
    PubMed         Abstract available

  44. BASHIR MA, Awoonor-Williams JK, Amponsah-Manu F
    Prevalence of fever and its associated risk factors among patients hospitalised with coronavirus disease 2019 (COVID-19) at the Eastern Regional Hospital, Koforidua, Ghana.
    PLoS One. 2024;19:e0296134.
    PubMed         Abstract available

  45. BEN-UMEH KC, Kim J
    Income disparities in COVID-19 vaccine and booster uptake in the United States: An analysis of cross-sectional data from the Medical Expenditure Panel Survey.
    PLoS One. 2024;19:e0298825.
    PubMed         Abstract available

  46. BALEGHA AN, Abdul-Aziz S, Mornah L
    Healthcare professionals' perception and COVID-19 vaccination attitudes in North-Western Ghana: A multi-center analysis.
    PLoS One. 2024;19:e0298810.
    PubMed         Abstract available

  47. BRADY SM, Salway R, Mariapun J, Millard L, et al
    Accelerometer-measured 24-hour movement behaviours over 7 days in Malaysian children and adolescents: A cross-sectional study.
    PLoS One. 2024;19:e0297102.
    PubMed         Abstract available

  48. JEONG HS, Chun BC
    COVID-19 vaccine safety: Background incidence rates of anaphylaxis, myocarditis, pericarditis, Guillain-Barre Syndrome, and mortality in South Korea using a nationwide population-based cohort study.
    PLoS One. 2024;19:e0297902.
    PubMed         Abstract available

  49. YAFFE MJ, McCusker J, Lambert SD, Haggerty J, et al
    Self-care interventions to assist family physicians with mental health care of older patients during the COVID-19 pandemic: Feasibility, acceptability, and outcomes of a pilot randomized controlled trial.
    PLoS One. 2024;19:e0297937.
    PubMed         Abstract available

  50. ROSEN J, Frykholm P, Jonsson Fagerlund M, Pellegrini M, et al
    Lung impedance changes during awake prone positioning in COVID-19. A non-randomized cross-over study.
    PLoS One. 2024;19:e0299199.
    PubMed         Abstract available

  51. ADINKRAH EK, Bazargan S, Cobb S, Kibe LW, et al
    Mobilizing faith-based COVID-19 health ambassadors to address COVID-19 health disparities among African American older adults in under-resourced communities: A hybrid, community-based participatory intervention.
    PLoS One. 2024;19:e0285963.
    PubMed         Abstract available

  52. LEGGETT H, Vinall-Collier K, Csikar J, Barber S, et al
    Legacy lessons from the COVID-19 era to improve trial participation and retention: Views from trial participants, PPIE contributors and trial staff across the NIHR portfolio.
    PLoS One. 2024;19:e0296343.
    PubMed         Abstract available

  53. TINJIC D, Norden A
    Crisis-driven digitalization and academic success across disciplines.
    PLoS One. 2024;19:e0293588.
    PubMed         Abstract available

  54. SHAIK M, Rabbani MR, Atif M, Aysan AF, et al
    The dynamic volatility nexus of geo-political risks, stocks, bond, bitcoin, gold and oil during COVID-19 and Russian-Ukraine war.
    PLoS One. 2024;19:e0286963.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  55. RAINS SA, Richards AS
    US state vaccine mandates did not influence COVID-19 vaccination rates but reduced uptake of COVID-19 boosters and flu vaccines compared to bans on vaccine restrictions.
    Proc Natl Acad Sci U S A. 2024;121:e2313610121.
    PubMed         Abstract available


    Vaccine

  56. KOLANDAI K, Milne B, von Randow M, Bullen C, et al
    Public opinion on global COVID-19 vaccine procurement and distribution policies: A nationally representative survey in Aotearoa New Zealand 2022.
    Vaccine. 2024 Feb 6:S0264-410X(24)00115-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  57. MIYAMOTO S, Suzuki T
    Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
    Vaccine. 2024 Feb 2:S0264-410X(24)00112-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  58. BENNETT JC, Luiten KG, O'Hanlon J, Han PD, et al
    Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection.
    Vaccine. 2024 Feb 1:S0264-410X(24)00103-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  59. DATTA S, Vattiato G, Maclaren OJ, Hua N, et al
    The impact of Covid-19 vaccination in Aotearoa New Zealand: A modelling study.
    Vaccine. 2024 Feb 1:S0264-410X(24)00128-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  60. SOOD S, Matar MM, Kim J, Kinsella M, et al
    Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer.
    Vaccine. 2024 Jan 31:S0264-410X(24)00077-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  61. JI Y, Sui X, Miao W, Wang C, et al
    Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
    Vaccine. 2024 Jan 30:S0264-410X(24)00097-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  62. SHAPIRO BEN DAVID S, Baruch Gez S, Adler L, Kovatch R, et al
    Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey.
    Vaccine. 2024 Jan 27:S0264-410X(24)00067-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  63. BALSELLS E, Vicente M, Reyes S, Figueroa M, et al
    Impact of the 'Health on Wheels' (HoW) strategy on COVID-19 vaccination coverage in hard-to-reach communities in Alta Verapaz, Guatemala, 2022.
    Vaccine. 2024 Jan 27:S0264-410X(24)00033-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  64. OKPANI AI, Adu P, Paetkau T, Lockhart K, et al
    Are COVID-19 vaccination mandates for healthcare workers effective? A systematic review of the impact of mandates on increasing vaccination, alleviating staff shortages and decreasing staff illness.
    Vaccine. 2024 Jan 27:S0264-410X(24)00052-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  65. TAKALANI A, Robinson M, Jonas P, Bodenstein A, et al
    Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.
    Vaccine. 2024 Jan 25:S0264-410X(24)00078-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  66. RUSS S, Bennett N, van Wijngaarden E, Hill E, et al
    Influence of Community Determinants on Barriers and Facilitators to COVID-19 Vaccine Uptake: Regional Stakeholders' Perspectives.
    Vaccine. 2024 Jan 24:S0264-410X(24)00051-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  67. HAMAD SAIED M, van Straalen JW, de Roock S, Verduyn Lunel FM, et al
    Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study.
    Vaccine. 2024 Jan 22:S0264-410X(24)00059-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  68. PAL R, Ferrari MG, Honda-Okubo Y, Wattay L, et al
    Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.
    Vaccine. 2024 Jan 22:S0264-410X(24)00034-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  69. HILL PL, Morstead T, Pfund GN, Burrow AL, et al
    Examining changes in sense of purpose before, during, and after COVID-19 vaccination.
    Vaccine. 2024 Jan 20:S0264-410X(24)00027-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  70. KING ML
    How manufacturing won or lost the COVID-19 vaccine race.
    Vaccine. 2024 Jan 15:S0264-410X(23)01477-9. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  71. HINSON-ENSLIN AM, Espinoza LE
    The mental health symptoms of individuals with sensory disabilities and the reasons that lead to COVID-19 vaccine refusal and hesitancy.
    Vaccine. 2024 Jan 9:S0264-410X(24)00012-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  72. MESIDOR M, Liu Y, Talbot D, Skowronski DM, et al
    Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology review.
    Vaccine. 2023 Dec 9:S0264-410X(23)01446-9. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  73. SATHE N, Shaikh S, Bhavsar M, Parte L, et al
    Safety, immunogenicity and efficacy of Relcovax(R), a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus.
    Vaccine. 2023 Oct 8:S0264-410X(23)01176-3. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available


    Virology

  74. ALTINA NH, Maranon DG, Anderson JR, Donaldson MK, et al
    The leader RNA of SARS-CoV-2 sequesters polypyrimidine tract binding protein (PTBP1) and influences pre-mRNA splicing in infected cells.
    Virology. 2024;592:109986.
    PubMed         Abstract available

  75. VALLERIANI F, Di Pancrazio C, Spedicato M, Di Teodoro G, et al
    A cell-adapted SARS-CoV-2 mutant, showing a deletion in the spike protein spanning the furin cleavage site, has reduced virulence at the lung level in K18-hACE2 mice.
    Virology. 2024;592:109997.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.